Natera (NTRA) Expected to Post Quarterly Earnings on Thursday

Natera (NASDAQ:NTRA) is expected to be announcing its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.2812) per share and revenue of $707.54 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.02. The company had revenue of $752.75 million during the quarter, compared to the consensus estimate of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The company’s quarterly revenue was up 37.7% on a year-over-year basis. During the same period in the prior year, the business posted ($0.74) EPS. On average, analysts expect Natera to post ($1.14) EPS for the current fiscal year and ($0.10) EPS for the next fiscal year.

Natera Trading Up 3.3%

NASDAQ NTRA opened at $424.42 on Thursday. Natera has a 12 month low of $181.00 and a 12 month high of $437.41. The company has a market cap of $61.18 billion, a PE ratio of -312.07 and a beta of 1.50. The stock has a 50 day moving average of $373.05 and a 200-day moving average of $264.53.

Insider Transactions at Natera

In other news, insider Solomon Moshkevich sold 3,000 shares of the stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $414.22, for a total value of $1,242,660.00. Following the sale, the insider directly owned 106,914 shares of the company’s stock, valued at approximately $44,285,917.08. This represents a 2.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider John Fesko sold 6,517 shares of the company’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $321.53, for a total value of $2,095,411.01. Following the completion of the transaction, the insider owned 197,257 shares in the company, valued at $63,424,043.21. This represents a 3.20% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 38,224 shares of company stock valued at $12,347,229. Corporate insiders own 5.05% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on NTRA. Stephens lifted their price objective on shares of Natera from $305.00 to $350.00 and gave the company an “overweight” rating in a research note on Wednesday, August 12th. Citigroup lifted their price target on shares of Natera from $365.00 to $480.00 and gave the stock a “buy” rating in a report on Tuesday, October 6th. TD Cowen increased their price target on Natera from $340.00 to $480.00 and gave the stock a “buy” rating in a report on Tuesday, October 13th. Barclays lifted their price target on shares of Natera from $340.00 to $475.00 and gave the company an “overweight” rating in a research note on Wednesday, October 7th. Finally, Piper Sandler boosted their price objective on Natera from $249.00 to $363.50 and gave the company an “overweight” rating in a report on Wednesday, August 12th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $394.31.

Natera Company Profile

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.